行情

EGRX

EGRX

Eagle制药
NASDAQ

实时行情|Nasdaq Last Sale

56.41
-0.52
-0.91%
交易中 11:48 01/27 EST
开盘
55.90
昨收
56.93
最高
56.62
最低
55.52
成交量
2.03万
成交额
--
52周最高
64.94
52周最低
38.38
市值
7.71亿
市盈率(TTM)
31.67
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

EGRX 新闻

  • Eagle Pharmaceuticals to Develop Dantrolene Sodium for Potential Treatment of Alzheimer’s Disease in Collaboration With University of Pennsylvania
  • Business Wire.01/13 11:50
  • Tyme Technologies: Why Investors Should Be Bullish On The Eagle Partnership
  • Seeking Alpha - Article.01/13 03:08
  • Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study
  • Zacks.01/09 13:40
  • Eagle Pharma Reports Resubmission Of New Drug Application For RYANODEX For Exertional Heat Stroke
  • Benzinga.01/09 11:50

更多

所属板块

制药
-0.37%
制药与医学研究
-0.52%

热门股票

名称
价格
涨跌幅

EGRX 简况

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
展开

Webull提供Eagle Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。